Status:
COMPLETED
Study of Attention and Memory Treatments for Cancer Survivors
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Akili Interactive Labs, Inc.
Conditions:
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This clinical trial investigates if certain electronic games may be effective in improving attention and memory function in cancer survivors. Cancer related cognitive impairment (CRCI) is an issue exp...
Detailed Description
PRIMARY OBJECTIVES: I. Determine the recruitment and retention rates for both arms of this study. II. Determine the effect size for changes in cognitive function (i.e., Test of Variables of Attention...
Eligibility Criteria
Inclusion
- Attention Function Index (AFI) score of \< 7.5
- Are able to read, write, and understand English
- Ability to understand an electronic informed consent document, and the willingness to sign it
- Have a Karnofsky performance status (KPS) score of \>= 50
- Have access to WiFi connection
Exclusion
- Receiving active treatment for cancer recurrence
- Have significant cognitive impairment
- Have sensory or motor deficits that prevent them from doing the assessment and using the application
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04870320
Start Date
March 1 2021
End Date
January 31 2022
Last Update
April 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California San Francisco
San Francisco, California, United States, 94143